Shares of OBI Pharma Inc (台灣浩鼎) yesterday fell by the maximum daily limit of 10 percent to close at NT$613, after the company on Sunday released discouraging results on the second and third-phase clinical trials of a new breast cancer drug, OBI-822.
OBI-822 remains an effective treatment option and the trial’s less promising than expected outcome stemmed from a number of factors, OBI Pharma chairman Michael Chang (張念慈) told an investors’ conference yesterday.
The drug is designed to target Globo H, an oligosaccharide tumor antigen, by triggering the human body’s immune system to generate antibodies that activate cytotoxic T cells to destroy cancer cells, and more than 80 percent of the participants in the trials had generated immune system responses, he said.
Among the participants who showed immune responses, most had made good progress in recovery, while maintaining a safe level of toxicity of the drug.
“About 20 percent of participants did not generate immune responses, and their results should not have been included in the study,” Chang said.
The parameters of the study were set in 2009, and the company elected to go ahead with the trials even though it had discovered flaws in the methodology, he said.
In addition, the study had neglected to select participants based on whether they showed an ample presence of Globo H, Chang said.
Immune responses are not statistically significant without the oligosaccharide, he said.
The flawed design of the study prematurely ruled out many potential participants before they had time to go through the eight-to-nine-week dormant period it is believed to take for the immune responses to develop, he said.
Chang said that he and the company’s other major stakeholders are planning to initiate a share buyback program.
Academia Sinica President Wong Chi-huey (翁啟惠), a close collaborator with the company, said he considers an 80 percent immune response as a statistically successful outcome, in particular among people in the more terminal stages of their diseases, who have diminished immune systems.
The objective of clinical trials is to determine which drugs prove to be effective and the focus should be placed on the outcome of participants who have developed an immune response, Wong said.
Excluding those without an immune response would present a more statistically significant outcome, Wong said, and he urged health authorities to devise new criteria for different treatments.
Yesterday’s plunge in OBI Pharma shares dragged down the biotechnology and medical care sub-index on the Taipei Exchange, which fell 5.17 percent to 178.9 points, the lowest since November last year, with many other high-priced sector leaders also seeing steep declines, TPEX data showed.
Analysts said that they do not expect a catastrophic crash in OBI Pharma share prices, as the company’s backers include the deep-pocketed Runtex Group (潤泰集團).
HORMUZ ISSUE: The US president said he expected crude prices to drop at the end of the war, which he called a ‘minor excursion’ that could continue ‘for a little while’ The United Arab Emirates (UAE) and Kuwait started reducing oil production, as the near-closure of the crucial Strait of Hormuz ripples through energy markets and affects global supply. Abu Dhabi National Oil Co (ADNOC) is “managing offshore production levels to address storage requirements,” the company said in a statement, without giving details. Kuwait Petroleum Corp said it was lowering production at its oil fields and refineries after “Iranian threats against safe passage of ships through the Strait of Hormuz.” The war in the Middle East has all but closed Hormuz, the narrow waterway linking the Persian Gulf to the open seas,
Nanya Technology Corp (南亞科技) yesterday said the DRAM supply crunch could extend through 2028, as the artificial intelligence (AI) boom has led the world’s major memory makers to dramatically reduce production of standard DRAM and allocate a significant portion of their capacity for high-bandwidth memory (HBM) chips. The most severe supply constraints would stretch to the first half of next year due to “very limited” increases in new DRAM capacity worldwide, Nanya Technology president Lee Pei-ing (李培瑛) told a news briefing. The company plans to increase monthly 12-inch wafer capacity to 20,000 in the first half of 2028 after a
Taiwan has enough crude oil reserves for more than 100 days and sufficient natural gas reserves for more than 11 days, both above the regulatory safety requirement, Minister of Economic Affairs Kung Ming-hsin (龔明鑫) said yesterday, adding that the government would prioritize domestic price stability as conflicts in the Middle East continue. Overall, energy supply for this month is secure, and the government is continuing efforts to ensure sufficient supply for next month, Kung told reporters after meeting with representatives from business groups at the ministry in Taipei. The ministry has been holding daily cross-ministry meetings at the Executive Yuan to ensure
Property transactions in the nation’s six special municipalities plunged last month, as a lengthy Lunar New Year holiday combined with ongoing credit tightening dampened housing market activity, data compiled by local land administration offices released on Monday showed. The six cities recorded a total of 10,480 property transfers last month, down 42.5 percent from January and marking the second-lowest monthly level on record, the data showed. “The sharp drop largely reflected seasonal factors and tighter credit conditions,” Evertrust Rehouse Co (永慶房屋) deputy research manager Chen Chin-ping (陳金萍) said. The nine-day Lunar New Year holiday fell in February this year, reducing
RSS